Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

1373 ARTÍCULOS , VIENDO DEL 61 AL 75

Memantine-associated renal impairment in a patient with Alzheimer's disease

Horikawa N, Yamada H, Uchimura N.

Psychiatry Clin Neurosci. 2013 Feb;67(2):126. doi: 10.1111/pcn.12020.

Role of statins in Alzheimer's disease: a retrospective meta-analysis for commonly investigated clinical parameters in RCTs

Pandey RD, Gupta PP, Jha D, Kumar S.

Int J Neurosci. 2013 Aug;123(8):521-5. doi: 10.3109/00207454.2013.778846. Epub 2013 Apr 9.

[Speech and communication: "what do you want from me?"]

Werner S.

Pflege Z. 2013 Feb;66(2):122-3.

Alzheimer's disease: which type of amyloid-preventing drug agents to employ?

Jang H, Connelly L, Arce FT, Ramachandran S, Lal R, Kagan BL, Nussinov R.

Phys Chem Chem Phys. 2013 Jun 21;15(23):8868-77. doi: 10.1039/c3cp00017f. Epub 2013 Feb 28.

Advances with RNA interference in Alzheimer's disease research

Chen S, Ge X, Chen Y, Lv N, Liu Z, Yuan W.

Drug Des Devel Ther. 2013;7:117-25. doi: 10.2147/DDDT.S40229. Epub 2013 Feb 22.

High-dose donepezil (23 mg/day) for the treatment of moderate and severe Alzheimer's disease: drug profile and clinical guidelines

Cummings JL, Geldmacher D, Farlow M, Sabbagh M, Christensen D, Betz P.

CNS Neurosci Ther. 2013 May;19(5):294-301. doi: 10.1111/cns.12076. Epub 2013 Mar 6.

Vascular oxidative stress and mitochondrial failure in the pathobiology of Alzheimer's disease: a new approach to therapy

Sochocka M, Koutsouraki ES, Gasiorowski K, Leszek J.

CNS Neurol Disord Drug Targets. 2013 Sep;12(6):870-81. doi: 10.2174/18715273113129990072.

Novel tacrine-related drugs as potential candidates for the treatment of Alzheimer's disease

Romero A, Cacabelos R, Oset-Gasque MJ, Samadi A, Marco-Contelles J.

Bioorg Med Chem Lett. 2013 Apr 1;23(7):1916-22. doi: 10.1016/j.bmcl.2013.02.017. Epub 2013 Feb 16.

Progress and developments in tau aggregation inhibitors for Alzheimer disease

Bulic B, Pickhardt M, Mandelkow E.

J Med Chem. 2013 Jun 13;56(11):4135-55. doi: 10.1021/jm3017317. Epub 2013 Mar 13.

Reconsider Alzheimer's disease by the 'calpain-cathepsin hypothesis'--a perspective review

Yamashima T.

Prog Neurobiol. 2013 Jun;105:1-23. doi: 10.1016/j.pneurobio.2013.02.004. Epub 2013 Mar 15.

Structure-based design of β-site APP cleaving enzyme 1 (BACE1) inhibitors for the treatment of Alzheimer's disease

Yuan J, Venkatraman S, Zheng Y, McKeever BM, Dillard LW, Singh SB.

J Med Chem. 2013 Jun 13;56(11):4156-80. doi: 10.1021/jm301659n. Epub 2013 Apr 5.

The validity of dependence as a health outcome measure in Alzheimer's disease

Spackman DE, Kadiyala S, Neumann PJ, Veenstra DL, Sullivan SD.

Am J Alzheimers Dis Other Demen. 2013 May;28(3):245-52. doi: 10.1177/1533317513481092. Epub 2013 Mar 19.

A comprehensive review on synthesis and designing aspects of coumarin derivatives as monoamine oxidase inhibitors for depression and Alzheimer's disease

Patil PO, Bari SB, Firke SD, Deshmukh PK, Donda ST, Patil DA.

Bioorg Med Chem. 2013 May 1;21(9):2434-50. doi: 10.1016/j.bmc.2013.02.017. Epub 2013 Feb 27.

The safety, tolerability, pharmacokinetics and cognitive effects of GSK239512, a selective histamine H₃ receptor antagonist in patients with mild to moderate Alzheimer's disease: a preliminary investigation

Nathan PJ, Boardley R, Scott N, Berges A, Maruff P, Sivananthan T, Upton N, Lowy MT, Nestor PJ, Lai R.

Curr Alzheimer Res. 2013 Mar;10(3):240-51. doi: 10.2174/1567205011310030003.

Do angiotensin receptor blockers protect against Alzheimer's disease?

Kurinami H, Shimamura M, Sato N, Nakagami H, Morishita R.

Drugs Aging. 2013 Jun;30(6):367-72. doi: 10.1007/s40266-013-0071-2.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias